Targeting the dark genome to tackle obesity
This issue of our newsletter is supported by Inpart.
In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1 billion deal with Eli Lilly to apply its long non-coding RNA (lncRNA) technology to obesity. The CEO and co-founder of Haya Therapeutics, Samir Ounzain, is one of the first researchers to publish on lncRNA – also known as the “dark genome”.
But what exactly is the “dark genome” and what makes it a good target for tackling disease? This week on the Beyond Biotech podcast, Samir Ounzain provides us with answers to these questions, and also tells us more about the work being done by Haya Therapeutics.?
To find out more, listen to the full episode: “Targeting the dark genome to develop new therapies to fight obesity”?
A MESSAGE FROM OUR SPONSOR INPART
A life science CRM for the times: why are top pharma seeking end-to-end partnering solutions?
Discover why BD&L, Alliance Management, and Open Innovation teams are looking for end-to-end partnering solutions, the drawbacks of household CRMs, and how Inpart's Deal platform outperforms traditional platforms for identifying, tracking and securing partnerships.
Want to advertise with us? Become our next sponsor.
?? More noteworthy articles from this week:
Bottlenecks can occur at various stages of the vaccine supply chain, including shortages of vaccine ingredients, packaging materials, and fill-and-finish facilities. Needle-free vaccines, however, could be the answer to solving many of these bottlenecks, as they are manufactured differently from traditional needle-based vaccines. Additionally, needle-free vaccines can also be self-administered at home by patients or their caregivers, removing a significant burden in vaccine delivery.?
The year 2025 kicked off in full swing with several biotech deals in the industry. While recurring collaborators such as GSK and Eli Lilly shopped around for therapeutic programs, newly-launched biotechs also stood out among collaborations last month. As usual, small molecules, antibody-drug conjugates (ADCs), and monoclonal antibodies were industry favorites.
Scientists have made significant advances in treating Alzheimer’s, with monoclonal antibodies emerging as a major stride to stop progression and address symptoms. A new trial led by Washington University School of Medicine (WashU Medicine) in the U.S. is investigating a monoclonal antibody that could potentially halt Alzheimer’s decades before it begins to progress.
Biotechnology is uniquely positioned to replace polluting materials and chemical processes with more sustainable, biological alternatives. This scientific field draws from millions of years of evolution in which living beings have specialized in producing and recycling all kinds of compounds and materials. These biological processes can be used to efficiently break down waste and produce materials with lower pollution, water, land, and energy use than traditional methods.
Currently, subcutaneous delivery – via needle-based syringes or pens – is the common route of administration for GLP-1 receptor agonists. However, this route is associated with several drawbacks Sublingual delivery could be a more patient friendly alternative: it is easy, fast, reliable and may even reduce a number of side effects.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.